Navigation Links
UbiVac Announces Collaboration with Johnson & Johnson Innovation to Develop and Test, in Preclinical Studies, a Vaccine to Intercept Oral Cancer
Date:9/29/2015

PORTLAND, Ore., Sept. 29, 2015 /PRNewswire/ -- UbiVac, www.ubivac.com, a privately held clinical stage Immuno-Oncology company, has announced today a collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The Johnson & Johnson Innovation Center in California facilitated the research agreement on behalf of the Janssen Disease Interception Accelerator.

Under the terms of the agreement, UbiVac will develop new preclinical and clinical versions of its proprietary DRibble® immunotherapy for use in preclinical studies of oral cancer. UbiVac will receive an upfront payment, plus additional financial commitments, contingent upon reaching certain pre-determined research, development and manufacturing milestones. In addition to funding the research, Janssen has an option for further development and licensing of the new DRibble immunotherapy.

Many oral cancers develop from oral leukoplakia, a white lesion that develops in the oral cavity and is estimated to affect 2 percent of the global population. The World Health Organization defines this as a potentially malignant condition, with 1 percent of lesions progressing to oral cancer annually. It is unknown if surgical excision eliminates the risk of developing oral cancer. Thus, development of an immunotherapy that induced broad anti-cancer immunity and inhibited oral leukoplakia from transforming into oral cancer would represent a paradigm shift for treating this disease.

"We are excited about this collaboration with Janssen to evaluate UbiVac's DRibble technology as a potential approach for intercepting oral cancer," Bernard A. Fox, chief executive officer, UbiVac said. "The development of a vaccine for cancer has long been a dream of UbiVac. This project provides a scientific partner and the resources that could make that dream a reality."

About UbiVac.

UbiVac is a clinical stage Immuno-Oncology company engaged in development of immunotherapies to combat cancer. UbiVac's DPV-001 is currently in a phase II randomized multicenter adjuvant study for non-small cell lung cancer. UbiVac has ongoing preclinical and discovery programs using DRibble®, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005, by Drs. Bernard A Fox and Hong-Ming Hu, UbiVac is a spinout of the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University, created UbiVac CMV to license sdCMV.

Logo - http://photos.prnewswire.com/prnh/20150929/271692LOGO

 


'/>"/>
SOURCE UbiVac
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. UbiVac Opens Trial of Next Generation Lung Cancer Vaccine
2. Pharmagen Announces First Quarter 2013 Results
3. Aoxing Pharmaceutical Company, Inc. Announces Financial Results For Third Quarter Of 2013 Fiscal Year
4. Vasomedical Announces Financial Results for the First Quarter of 2013
5. TSI Announces 2013 Respiratory Protection Roadshow Training Dates and Locations
6. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
7. Active Life Announces $500K Follow On Series A Investment - Tech Coast Angels Re-up
8. Pentec Health Announces Limited Voluntary Recall of Certain Compounded Prescription Therapies for Renal Patients
9. DebMed Announces US Patent
10. Physician-Patient Alliance for Health & Safety Announces Four Essentials for Safety for Patients Receiving Opioids
11. Lakewood-Amedex Announces Results Demonstrating The More Rapid Direct Bactericidal Activity Of Novel Bisphosphocin Class Of Antimicrobials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2020)... , ... April 02, 2020 , ... ... freshman has won SignatureCare Emergency Center's 2020 Spring Semester Scholarship. , ... to the medical and healthcare field, is aimed at helping the students pay ...
(Date:4/1/2020)... ... April 01, 2020 , ... The new ... today, with the first live-streaming broadcast premiering on April 2. , The live ... interviewing a variety of animal keepers and veterinary hospital staff with different animals. ...
(Date:3/30/2020)... ... ... FastMed Urgent Care , one of the nation’s largest urgent care providers, ... offering its COVID-19 self-assessment tool as a free public service to help patients quickly ... that help assess the risk of coronavirus. , While FastMed is currently not ...
Breaking Medicine Technology:
(Date:4/5/2020)... ... April 04, 2020 , ... MyAdvisor, a ... uniting with the Yellow Ribbon Fund (YRF) to offer mental health and care ... continuing an ongoing partnership to launch a new initiative throughout the global COVID-19 ...
(Date:4/2/2020)... CHURCH, Va. (PRWEB) , ... April 02, 2020 ... ... Clinical Decision Support Software, An FDAnews Webinar, Tuesday April 7, 2020, 1:30-3:00 p.m. ... updated to include FDA regulation of AI used to guide clinical management of ...
(Date:4/2/2020)... ... April 02, 2020 , ... Representatives fighting for ... encouraging their parents, grandparents, and guardians, to file a proof of claim in ... funds will be made available by Purdue as part of its bankruptcy settlement. ...
(Date:4/1/2020)... ... April 01, 2020 , ... American hospital ... while treating Coronavirus-infected patients. , Staffers are in particular need of face shields, ... this week, The Wall Street Journal reported that New York City mayor Bill ...
(Date:3/30/2020)... DIEGO (PRWEB) , ... March 30, 2020 , ... ... to new and prospective patients, continuing its commitment to provide comprehensive and compassionate ... , Patients can use Achieve Medical Center’s UpDox platform for telemedicine services including ...
Breaking Medicine News(10 mins):